Status:

COMPLETED

Nortriptyline for Idiopathic Gastroparesis

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Idiopathic Gastroparesis

Eligibility:

All Genders

21-65 years

Phase:

PHASE3

Brief Summary

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.

Eligibility Criteria

Inclusion

  • Age 21 through 65 years old at registration
  • Documentation of delayed gastric emptying on gastric emptying scintigraphy within 2 years of registration, defined as greater than 60% retention at 2 hours or greater than 10% retention at 4 hours
  • Symptoms of gastroparesis for at least 6 months (does not have to be contiguous) prior to registration with Gastroparesis Cardinal Symptom Index (GCSI) score of 21 or greater
  • Negative upper endoscopy or upper GI series within 2 years of registration

Exclusion

  • Normal gastric emptying confirmed with scintigraphy
  • Diabetic gastroparesis or post-surgical gastroparesis including fundoplication
  • Another active disorder which could explain symptoms in the opinion of the investigator
  • History of significant cardiac arrhythmias and/or prolonged QTc
  • History of seizures
  • Use of narcotics more than 3 days per week
  • Use of tricyclic antidepressants for refractory symptoms of gastroparesis within 6 weeks prior to randomization
  • Use of strongly anticholinergic medications
  • Use of calcium channel blockers
  • Use of erythromycin
  • Clear history of failed trial of nortriptyline use for gastroparetic symptoms
  • Symptoms of primary depression or suicidal ideation
  • Contraindications to nortriptyline:
  • hypersensitivity or allergy to any tricyclic antidepressant drug
  • concomitant therapy with a monoamine oxidase inhibitor (MAOI)
  • recent myocardial infarction
  • glaucoma
  • Pregnancy or nursing
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study
  • Use of a G tube, J tube,or a central catheter for nutrition
  • Use of a gastric electrical stimulator
  • Failure to give informed consent

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT00765895

Start Date

January 1 2009

End Date

October 1 2012

Last Update

May 14 2020

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

California Pacific Medical Center

San Francisco, California, United States, 94115

2

Stanford University

Stanford, California, United States, 94305-5187

3

University of Michigan Medical Center

Ann Arbor, Michigan, United States, 48109

4

University of Mississippi Medical Center

Jackson, Mississippi, United States, 39216